This open-label, single-site, pilot study evaluated the therapeutic usefulness of topiramate in five children with typical absence seizures defined as loss of awareness associated with 3 Hz spike-wave activity on 24 hour ambulatory electroencephalogram (EEG). The children were previously untreated or treated unsuccessfully using other antiepileptic medication. Topiramate was initiated at a dose of 1 mg kg −1 day −1 , titrated twice weekly in 1 mg kg −1 day −1 increments to 12 mg kg −1 day −1 or individual maximally tolerated dose. Response was assessed after 6 weeks with ambulatory EEG monitoring and patient/parent record of seizure counts. All children completed the study. One previously untreated child became seizure-free on 5 mg kg −1 day −1 topiramate, with no residual spike-wave activity at the final visit. In two patients, the frequency of seizures decreased in the early phases of titration, but rose to baseline levels as the topiramate dose was increased. With a reduction in dose to 6 mg kg −1 day −1 , seizure control improved, with substantial reductions in spike-wave activity. Seizure counts were not improved in the two remaining patients. Transient mood changes were noted in two patients. No child was withdrawn secondary to adverse effects. The results suggest that topiramate may be effective in childhood absence epilepsy. Controlled studies are now required to identify the clinically optimal dose.
INTRODUCTION
Childhood absence epilepsy is an idiopathic generalized epilepsy syndrome characterized by frequent absence seizures which take the form of brief impairments of consciousness, usually with an abrupt onset and offset. Absence seizures account for 2-11% of all seizure types. In childhood absence epilepsy they typically emerge between the ages of 5 and 10 years 1 , often occurring upwards of 20 times a day 2 . In addition to interference with daily activities, absences present a serious risk of accidental injury 3 . Although affected children are generally of normal intelligence, childhood absence epilepsy has the potential to negatively impact upon learning and academic performance.
Absence seizures generally respond promptly to treatment with conventional antiepileptic drugs (AEDs) such as sodium valproate and ethosuximide 1, 4 . However, ethosuximide has little effect on other seizure types. In addition, these drugs are known to produce adverse effects in ≥50% of patients 5, 6 , including somnolence, nausea, headache, dizziness and weight gain. These specific adverse effects are more prominent in patients receiving polytherapy than monotherapy, while idiosyncratic toxicities such as allergic dermatitis, pancreatitis and agranulocytosis are also reported 4 . The traditional AEDs carbamazepine and phenytoin are precluded in some generalized epilepsy syndromes, including childhood absence epilepsy, as these agents have been shown to exacerbate absence seizures 7, 8 .
Several novel AEDs such as topiramate, lamotrigine and gabapentin have recently been developed 9 . These are expected to be at least similar in efficacy (recently demonstrated with lamotrigine 10 ), but preferable in side-effect profile to the conventional portfolio of AEDs, indicating potential use in monotherapy applications.
Topiramate is presently indicated as both monotherapy and adjunctive therapy in adults and children (aged ≥ 2 years) with partial-onset seizures or primary generalized tonic-clonic seizures. In addition, topiramate is indicated as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome in both adults and children. In randomized controlled trials involving adults and children with epilepsy [11] [12] [13] [14] [15] (for review see Reference 16), topiramate did not appear to aggravate generalized seizures, including absence seizures. Beneficial effect on absence seizures was difficult to assess in such studies, however, as seizure frequency cannot be accurately determined by clinical evaluation alone 17, 18 .
To evaluate the efficacy of therapeutic agents in absence epilepsy, exact seizure counts can be reliably measured using 24 hour ambulatory electroencephalogram (EEG). This paper describes a pilot study utilizing EEG to evaluate the therapeutic usefulness of topiramate in childhood absence epilepsy. The study also aimed to generate information regarding the safe titration rate and minimal effective dose of topiramate.
METHODS
Five children (two boys, three girls; age range 6-11.5 years) entered this open-label, single-site, pilot study. Their demographics are shown in Table 1 . Absence seizures were the only type of seizure experienced by all children at entry to the study. Inclusion criteria required for the study are shown in Table 2 . The study had full approval from the local Research Ethics Committee. Informed consent was obtained from all parents/guardians.
Each parent was asked to keep a seizure diary for the duration of the study. More accurate documentation of episodes was achieved using 24 hour ambulatory EEG following a 3 minute period of hyperventilation. For inclusion in the study, the children were required to have typical absence seizures characterized by 3 Hz spike-wave discharges. Runs of 3 Hz spike-wave activity of ≥3 seconds were regarded as significant for the purpose of this study.
The protocol required previous AED therapy to have been discontinued at least 5 days before screening where possible. Seven days prior to the first dose of topiramate, at the screening visit, measurements were made of 24 hour ambulatory EEG, electrocardiogram (ECG), haematology, blood chemistry, urinalysis, and a full clinical evaluation including physical examination was performed.
Patients received oral topiramate at a starting dose of 1 mg kg −1 day −1 on a twice-daily (b.i.d.) regimen, commencing on day 1. The dose was titrated twice weekly in 1 mg kg −1 day −1 increments to 12 mg kg −1 day −1 over 6 weeks, seizure freedom prior to this dose, or the maximally tolerated dose for that individual. On the day prior to each dose increment, telephone contact was made with the parent. If a patient could not tolerate a given topiramate dose during the escalation phase, the titration time could be extended or the dose reduced. Patients controlled at 25 mg day −1 could receive topiramate on a oncedaily dose regimen. Haematology, blood chemistry and urinalysis measurements were repeated on days 15, 29 and 43 (final visit, week 6) with a repeat 24 hour ambulatory EEG taken at the final visit.
Clinical response was assessed at week 6 using data from 24 hour ambulatory EEG monitoring and a patient/parent diary of seizure counts. Efficacy was calculated using EEG results as a percentage reduction in 3 Hz spike-wave discharges of ≥3 seconds. Physical examination, medical history, ECG, haematology, blood chemistry and urinalysis measurements were also carried out.
RESULTS
Of the five children entering the study, three had previously been treated unsuccessfully using one or more AED (Table 1) . Of these, two (patients 2 and 3) had discontinued antiepileptic therapy at least 5 days prior to screening according to the study protocol. There was a departure from protocol in one patient (patient 4), who was still receiving sodium valproate at the screening visit. An attempted wean had been made but this had led to deterioration in seizure control after 2 weeks, prior to a complete wean of sodium valproate. He was therefore entered into the study, and sodium valproate was discontinued by day 13 of the protocol.
All five children completed the study. Individual results for each patient are presented in Table 3 . One previously untreated child (patient 1) achieved seizure freedom on a dose of 5 mg kg −1 day −1 topiramate, with no residual spike-wave activity on 24 hour EEG at the final visit. As clinical resolution was noted at this dose, confirmed by EEG, topiramate was not increased further. Subsequently this patient remained seizure-free for 2 years and has since been weaned from medication with no seizure recurrence.
In patients 2 and 3, absence seizures were reduced in the early phases of titration, but increased towards baseline levels as the topiramate dose increased to 12 mg kg −1 day −1 . With a dose reduction to 6 mg kg −1 day −1 , seizure control improved, and patient 2 became clinically seizure-free. Patient 3 showed maintained clinical improvement, with seizure counts reduced by >50% (from 390 episodes at study entry to 31 episodes at the end of the 6 week study period). Substantial reductions in EEG spike-wave duration were also observed for patients 2 and 3, both (Tables 1 and 3 ). For patients 4 and 5, no improvements in seizure counts were observed with topiramate treatment and only minimal changes in the EEG recordings were obtained. Patient 4 was tapered off sodium valproate over the course of the study period. As per protocol, sodium valproate was reduced with the intention of a complete wean prior to the introduction of topiramate. However, as sodium valproate was weaned there was an apparent increase in spike-wave activity. Topiramate was therefore introduced prior to a complete withdrawal of sodium valproate 13 days into the protocol. The introduction of topiramate returned the seizure frequency to baseline but there was no further improvement seen. The patient subsequently became seizure-free on a combination of sodium valproate and lamotrigine. Patient 5 was previously untreated. An attempt at dosage reduction from 12 to 6 mg kg −1 day −1 (seen to reduce seizure frequency in patients 2 and 3) did not improve the clinical outcome for this patient. Seizures were subsequently resistant to sodium valproate, but responded to high dose lamotrigine.
Transient mood changes were also reported in these two children, but no alterations in topiramate dose were required as a result, and in both they resolved spontaneously with no deviation from the protocol of titration. No other adverse events were observed in the study as a whole.
DISCUSSION
There is general agreement that childhood absence epilepsy has a favourable prognosis 19 . Treatment is often effective with conventional AEDs, but can be complicated by undesirable side effects. The availability of newer AEDs with the possibility of fewer adverse effects should lead to a steady improvement in therapeutic outcome. Monotherapy is the favoured approach to treatment. Lamotrigine is one of the newer agents recently shown to be effective as monotherapy in the treatment of absence epilepsy associated with 3 Hz spike-wave in comparison with placebo 10 .
Pre-clinical studies using the novel AED topiramate indicate a broad spectrum of anticonvulsant activity with multiple mechanisms of action 20 . Topiramate exhibits a favourable pharmacokinetic profile in humans, with rapid absorption, long duration of action and minimal interaction with other AEDs 16 . The present study attempts to evaluate the therapeutic usefulness of topiramate as monotherapy in five children with typical absence seizures. One previously untreated child became seizure-free, and seizure rates were reduced dramatically in two (one of whom became clinically seizure-free) whose previous AED therapy had failed. No deterioration in seizure frequency was apparent in any of the five children that could be attributed to treatment with topiramate. In this study, the minimal effective topiramate dose was 5 mg kg −1 day −1 . Rapid dose escalation (1 mg kg −1 day −1 increments twice weekly) was well tolerated. This may be presumed to be in contrast to experience in add-on studies of topiramate in generalized epilepsy and Lennox-Gastaut syndrome, where there was a relatively higher prevalence of central nervous system side effects where the titration had been more rapid 13, 15 . Controlled studies are now required, using gradual titration, to identify the clinically optimal dose of topiramate. Glauser 16 has suggested a starting dose for children of 0.5-1.0 mg kg −1 day −1 , with increases of 0.5-1.0 mg kg −1 day −1 every 1-2 weeks.
Efficacy, adverse event profiles and patient acceptance will be major contributory factors in determining the future roles of the newer AEDs, not least so in the paediatric population. Topiramate already has a role in the treatment of partial-onset epilepsy, generalized tonic-clonic seizures and Lennox-Gastaut syndrome. Preliminary data from the present study suggest that topiramate may also be useful for the treatment of childhood absence epilepsy, and certainly does not appear to be detrimental with regard to this seizure type.
